









Markets
/
Stocks
/
nasdaq-svra
/

Savara Inc

SVRA

5.300USD

+0.140+2.71%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

916.11MMarket Cap

LossP/E TTM



Savara Inc

5.300

+0.140+2.71%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Savara Inc

Currency: USD Updated: 2026-02-06

Key Insights

Savara Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 110 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.81.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Savara Inc's Score

Industry at a Glance

Industry Ranking

110 / 392

Overall Ranking

240 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Savara Inc Highlights

StrengthsRisks

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -9.88, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 181.72M shares, decreasing 6.32% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 12.48K shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

10.813

Target Price

+101.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Savara Inc is 5.22, ranking 376 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.22

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.62

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.66

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Savara Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Savara Inc is 6.31, ranking 299 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -9.88, which is -60.36% below the recent high of -3.91 and -70.96% above the recent low of -16.88.

Score

Industry at a Glance

Previous score

6.31

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 110/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Savara Inc is 8.75, ranking 61 out of 392 in the Biotechnology & Medical Research industry. The average price target is 10.25, with a high of 16.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.75

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

10.813

Target Price

+101.73%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Savara Inc

SVRA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Savara Inc is 6.78, ranking 171 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.16 and the support level at 4.77, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.60

Change

0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.146

Sell

RSI(14)

40.798

Neutral

STOCH(KDJ)(9,3,3)

17.407

Neutral

ATR(14)

0.331

Low Volatility

CCI(14)

-103.564

Sell

Williams %R

85.612

Oversold

TRIX(12,20)

-0.387

Sell

StochRSI(14)

40.357

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

5.400

Sell

MA10

5.522

Sell

MA20

5.753

Sell

MA50

6.003

Sell

MA100

4.960

Buy

MA200

3.858

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Savara Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 89.31%, representing a quarter-over-quarter increase of 2.73%. The largest institutional shareholder is The Vanguard, holding a total of 10.04M shares, representing 4.94% of shares outstanding, with 5.31% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

New Enterprise Associates (NEA)

24.47M

Bain Capital Life Sciences Investors, LLC

17.60M

Deerfield Management Company, L.P.

13.57M

+70.38%

VR Adviser, LLC

12.68M

+42.74%

TCG Crossover Management, LLC

12.36M

Frazier Life Sciences Management, L.P.

11.46M

The Vanguard Group, Inc.

Star Investors

8.31M

-1.44%

Nantahala Capital Management, LLC

8.78M

+5.41%

BlackRock Institutional Trust Company, N.A.

7.60M

-11.04%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Savara Inc is 4.59, ranking 80 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.